DoD Prostate Cancer, Idea Development Award

The DoD Prostate Cancer, Idea Development Award is a federal discretionary grant opportunity administered by the Department of Defense through the Department of the Army U.S. Army Medical Research Acquisition Activity under the Congressionally Directed Medical Research Programs. The opportunity is part of the fiscal year Prostate Cancer Research Program and is designed to support innovative and potentially transformative approaches to prostate cancer research. The program aligns with the broader mission of the Prostate Cancer Research Program, which seeks to advance research that will make meaningful contributions to understanding, preventing, diagnosing, and treating prostate cancer. The forecast notice emphasizes that all proposed projects must address one of the fiscal year Prostate Cancer Research Program Overarching Challenges, signaling that applications are expected to align closely with established programmatic priorities and strategic research goals. This funding opportunity is categorized under Science and Technology and other Research and Development and is associated with Assistance Listing 12.420 Military Medical Research and Development. The forecast estimates approximately eight awards with an estimated total program funding amount of $13,600,000. Although the forecast notice does not specify individual award ceilings or floors, the total anticipated funding and expected number of awards indicate a substantial federal investment in prostate cancer innovation research. The funding instrument type is a grant, and there is no cost sharing or matching requirement associated with the opportunity. The notice does not provide explicit restrictions on allowable costs, indirect costs, or project budgets, but applicants should expect additional guidance and detailed budget requirements when the full solicitation is released. The opportunity is open to unrestricted applicants, meaning entities of many different organizational types may apply, subject to any future clarifications included in the complete funding announcement. The forecast specifically highlights a New Investigator Category intended to encourage participation from investigators who are within ten years of completing their terminal degree. These applicants are required to identify collaborators with experience in prostate cancer research, demonstrating that the program places value on mentorship, interdisciplinary collaboration, and the integration of emerging researchers into established scientific networks. Because the eligibility notice is broad and unrestricted, the opportunity is expected to support participation from institutions of higher education, nonprofit research organizations, private research entities, and potentially other qualified organizations capable of conducting advanced biomedical research. The forecasted opportunity was posted on May 5, 2026, with an estimated official posting date of May 20, 2026. The estimated application due date is September 15, 2026. The estimated award date and project start date are both September 30, 2027, indicating a lengthy federal review and award administration timeline consistent with major biomedical research grant programs. The opportunity is currently in a forecasted stage because the application window has not officially opened. No separate pre-application requirement, letter of intent, or concept paper requirement is identified within the forecast notice. Similarly, the notice does not provide details regarding required submission forms, evaluation criteria, review phases, or proposal components, though these are likely to appear in the full funding announcement once released. Applications are expected to be managed through standard Department of Defense biomedical research grant systems, including eBRAP support services referenced in the notice. The eBRAP Help Desk is listed as the primary contact resource for applicants and can assist with technical or submission-related questions. The listed contact phone number is 301-682-5507 and the contact email is help@eBRAP.org. The notice also provides a reference link to an official Congressionally Directed Medical Research Programs press release page describing the fiscal year Prostate Cancer Research Program pre-announcement. While the current notice is only a forecast, interested applicants are encouraged to begin preparing research concepts, identifying collaborators, and monitoring the official posting for complete application instructions and submission requirements. The opportunity appears to be part of an annually recurring federal biomedical research funding cycle under the Congressionally Directed Medical Research Programs. Based on the fiscal year structure, estimated posting timeline, and recurring nature of the Prostate Cancer Research Program, applicants can reasonably anticipate future annual competitions even if the current cycle closes. Organizations interested in this opportunity should monitor Grants.gov and the Congressionally Directed Medical Research Programs website for the release of the full announcement package, detailed funding limitations, peer review criteria, allowable research scope, and formal application instructions. The program strongly emphasizes innovation, impactful scientific advancement, and alignment with Department of Defense prostate cancer research priorities.

Focus on innovative prostate cancer research concepts aligned with FY PCRP Overarching Challenges and establish experienced prostate cancer research collaborations for New Investigator applications.